[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577619":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Jemincare","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX003142","EXPERIMENTAL",null,[13],"Drug: JMKX003142 will be administered orally",{"label":15,"type":16,"description":11,"interventionNames":17},"placebo","PLACEBO_COMPARATOR",[18],"Drug: Plcacebo",[20,24],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","JMKX003142 will be administered orally",[9],{"type":21,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Plcacebo","matched to JMKX003142",[15],[29],{"name":30,"affiliation":31,"role":32},"Hong Zhang, Ph.D","Peking University First Hospital","STUDY_CHAIR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"xiaojun zhou","CONTACT","+8613717736760","zhouxiaojun@jemincare.com",[40],{"facility":31,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":30,"role":36,"phone":55,"phoneExt":11,"email":56},"010-83572211","hongzh@bjmu.edu.cn",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100577619","phase-2-trial-of-jmkx003142-in-participants-with-rapidly-progressive-autosomal-dominant-polycystic-kidney-disease-adpkd-100577619",false,"NCT06800651","Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Inclusion Criteria:\n\n* Able to understand the procedures of this trial and provide written informed consent voluntarily;\n* Age between 18 to 55 years, male or female;\n* ADPKD diagnostic criteria were met before randomization;\n* Rapidly progressive ADPKD criteria were met.\n\nExclusion Criteria:\n\n* 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period;\n* Praticipants who are unable to feel thirst, or have difficulty with fluid\u002Ffood intake;\n* Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;\n* The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.","ALL","18 Years","55 Years",{"count":70,"type":71},135,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[77],"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","2025-06-30",{"date":80,"type":81},"2025-07-03","ACTUAL",{"date":83,"type":81},"2025-03-13",{"date":85,"type":71},"2027-05-30",{"name":5,"class":6},1]